Skip to main content
Fig. 2 | Clinical and Translational Allergy

Fig. 2

From: Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management

Fig. 2

Modified from Bousquet et al. 2017 [45]

Effect of MP-AzeFlu, FP + LOR and placebo on nasal symptoms. Data are presented as mean change from baseline in total nasal symptom score (TNSS) assessed over a period of 4 h following exposure to ragweed pollen in an allergen exposure chamber. Arrow: onset of action; dotted arrow: onset to clinically relevant effect compared to placebo (i.e. 1.17 change in TNSS). MP-AzeFlu (MP-azelastine/fluticasone propionate; Dymista®; 1 spray/nostril; 138 μg/50 μg); FP (fluticasone propionate; Flonase®; 1 spray/nostril; 50 μg) + LOR (Loratadine; Claritin®; 10 mg). LS: least squares; SE: standard error. *p ≤ 0.005 vs placebo; p = 0.038 vs placebo; p ≤ 0.003 vs FP + LOR.

Back to article page